Working… Menu

PTX-200 and Carboplatin in Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01690468
Recruitment Status : Terminated (Enrollment stopped prior to Phase 1b, change in strategic focus)
First Posted : September 21, 2012
Last Update Posted : September 24, 2020
Information provided by (Responsible Party):
Prescient Therapeutics, Ltd.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 2019
Actual Study Completion Date : December 2019